Hang Hu is a male teacher affiliated with Changzhou University’s School of Pharmacy. He specializes in anticancer drug delivery, particularly in the sub-division of nanomedicine for cancer photodynamic therapy. Hang holds a teacher qualification and has significant experience in academia, research, and publications.
Author Profile:
ORCID Profile
Education
Hang Hu completed his Bachelor’s degree in Applied Chemistry from Hubei University. He pursued further studies, obtaining a Master’s degree in Organic Chemistry and later a Doctorate in Biopharmaceutical Engineering from Huazhong University of Science and Technology.
Research Focus
Hang Hu’s research primarily revolves around cancer photodynamic therapy, with a focus on developing novel strategies to enhance its effectiveness. He works on overcoming limitations such as tumor hypoxia and insufficient photosensitizer uptake through the development of smart nanomedicines and innovative drug combinations.
Professional Journey
Hang Hu began his professional journey with research during his graduate studies, focusing on constructing anticancer drug delivery systems. After obtaining his doctoral degree, he joined Changzhou University as a teacher in 2018, where he continues his research in cancer photodynamic therapy.
Honors & Awards
Hang Hu has received recognition for his contributions to the field, including awards for his research and publications. His work has been acknowledged by reputable journals and academic institutions.
Publications & Contributions
Hang Hu has co-authored over 40 SCI papers and holds over 30 invention patents in the field of anticancer drug delivery and cancer photodynamic therapy. His research has been recognized by Materials Today Bio, Journal of Colloid and Interface Science, and ACS Applied Materials & Interfaces, among others.
Targeted Delivery of Doxorubicin to Hepatoma Cells by Lactobionic Acid-Decorated Dual Redox-Responsive Polyethylene Glycol-Doxorubicin Nanoparticles
- Journal: International Journal of Nanoscience
- Published: 2023-06
- DOI: 10.1142/S0219581X23500199
- Contributors: Yang Fu, Chaohui Ji, Zhiheng Ma, Defeng Xu, Hang Hu
- Summary: This study focuses on enhancing the delivery of doxorubicin to hepatoma cells using nanoparticles decorated with lactobionic acid. The nanoparticles are designed to respond to redox conditions, providing targeted and responsive drug delivery.
Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy
- Journal: Materials Today Bio
- Published: 2023-02
- DOI: 10.1016/j.mtbio.2023.100542
- Contributors: Hang Hu, Defeng Xu, Qingbo Xu, Yuxiang Tang, Jun Hong, Yu Hu, Jianhao Wang, Xinye Ni
- Summary: This research introduces reduction-responsive nanoparticles for combined chemo-photodynamic therapy in cancer treatment. These nanoparticles offer a synergistic effect by combining chemotherapy and photodynamic therapy to enhance therapeutic outcomes.
Conjugates of lactobionic acid and IR820: New photosensitizers for efficient photodynamic therapy of hepatoma cells
- Journal: Drug Development Research
- Published: 2022-12
- DOI: 10.1002/ddr.22007
- Contributors: Xiaoyin Yuan, Yayu Tao, Wen Xiao, Kunda Du, Hang Hu, Defeng Xu, Qingbo Xu
- Summary: This study presents new photosensitizers composed of lactobionic acid and IR820 for efficient photodynamic therapy targeting hepatoma cells. These conjugates aim to improve the effectiveness of photodynamic therapy in treating liver cancer.
Mesoporous polydopamine-based multifunctional nanoparticles for enhanced cancer phototherapy
- Journal: Journal of Colloid and Interface Science
- Published: 2022-04
- DOI: 10.1016/j.jcis.2021.12.172
- Contributors: Hang Hu
- Summary: The research introduces multifunctional nanoparticles based on mesoporous polydopamine for enhanced cancer phototherapy. These nanoparticles likely offer multiple functionalities to improve the efficacy of phototherapy in cancer treatment.
Polyethylene glycol-modified mesoporous polydopamine nanoparticles co-loaded with dimethylcurcumin and indocyanine green for combination therapy of castration-resistant prostate cancer
- Journal: Journal of Drug Delivery Science and Technology
- Published: 2022-03
- DOI: 10.1016/j.jddst.2022.103158
- Contributors: Jun Hong, Yating Tang, Mengting Zhou, Jing Deng, Hang Hu, Defeng Xu
- Summary: This study presents nanoparticles co-loaded with dimethylcurcumin and indocyanine green, modified with polyethylene glycol, for combination therapy targeting castration-resistant prostate cancer. The combination therapy approach aims to improve treatment outcomes for this type of cancer.
Author Metrics
Hang Hu’s research output reflects his significant contributions to the field. With an H-index of 15 and numerous publications in high-impact journals, he has established himself as a prominent researcher in cancer photodynamic therapy.
Research Timeline
Hang Hu’s research journey began during his graduate studies, where he started working on constructing anticancer drug delivery systems. Since joining Changzhou University in 2018, he has continued to advance his research in cancer photodynamic therapy, focusing on developing innovative strategies to overcome its limitations.
